OTHER · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
Clinical trial
Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
NCT02465216
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
BIOLOGICAL · Unmapped registry intervention
ID93 + GLA-SE
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPhase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
PlaceboOTHER
ID93 + GLA-SEBIOLOGICAL
Sponsors & collaborators
Access to Advanced Health Institute (AAHI)lead sponsor
Wellcome Trustcollaborator
South African Tuberculosis Vaccine Initiativecollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02465216 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.